2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Bristol-Myers Squibb company profile · oncology, hematology, immunology & cardiovascular medicines · history · financial snapshot · S&P 500 rank #94 · 百時美施貴寶公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | BMY (NYSE) |
| Company | Bristol-Myers Squibb Company |
| GICS sector / industry | Health Care (XLV) / Pharmaceuticals |
| S&P 500 rank (by weight) | #94 · 0.18% (Oct 29, 2026) |
| Sector rank (by market cap) | #14 in Health Care (Oct 29, 2026) |
| Headquarters | Princeton, New Jersey |
| Founded | 1887, as Bristol-Myers Company (Squibb founded 1858) |
| CEO | Christopher S. Boerner (chairman and CEO) |
| Employees | ≈32,500 (Dec 31, 2025) |
| Market cap | $125.40B (Oct 29, 2026) · price $61.39 |
| SEC filings | EDGAR — CIK 0000014272 |
WHAT IT DOES
Bristol-Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and sells prescription medicines for serious diseases. It reports as a single segment, concentrated in oncology, hematology, immunology, cardiovascular disease and neuroscience. FY2025 total revenues were $48.19B, essentially flat on FY2024, with 69% from the United States.
Two blockbusters still anchor the top line: Eliquis, the oral anticoagulant co-marketed with Pfizer, at $14.44B, and Opdivo, the immuno-oncology antibody, at $10.05B. Around them, the Growth Portfolio — Reblozyl ($2.33B), Breyanzi ($1.36B), Camzyos ($1.07B), Opdualag ($1.19B) and Cobenfy ($155M in its first full year after approval) — grew 17% to $26.41B, while the Legacy Portfolio fell 15% to $21.79B as Revlimid ($2.95B) continued to lose ground to generics.
The strategy is a race against patent cliffs: replace Eliquis, Opdivo and Revlimid revenue with newer medicines and pipeline assets before exclusivity loss, while funding research from a $10.00B operating profit base. The BioNTech pumitamig collaboration, with a $1.5B upfront payment in 2025, is the largest single bet on that replacement.
BUSINESS SEGMENTS — FY2025 REVENUE BY PORTFOLIO
| Portfolio | Revenue | Share | YoY |
|---|---|---|---|
| Growth Portfolio | $26.41B | 54.8% | +17% |
| Legacy Portfolio | $21.79B | 45.2% | −15% |
| Total revenues | $48.19B | 100% | Essentially flat |
HISTORY
| 1858 | E. R. Squibb founds Squibb, a maker of pure pharmaceuticals |
| 1887 | William Bristol and John Myers found Bristol-Myers Company |
| 1989 | Bristol-Myers and Squibb merge as Bristol-Myers Squibb Company |
| 2012 | Eliquis (apixaban) wins US FDA approval for stroke prevention in atrial fibrillation |
| 2015 | Opdivo (nivolumab) wins US FDA approval, anchoring immuno-oncology |
| 2019 | Closes the Celgene acquisition, adding Revlimid and a hematology pipeline |
| 2020 | Acquires MyoKardia, adding Camzyos for obstructive hypertrophic cardiomyopathy |
| 2023 | Announces the Karuna Therapeutics acquisition, adding schizophrenia drug Cobenfy |
| 2024 | Cobenfy wins US FDA approval for schizophrenia; Karuna deal closes |
| 2025 | Enters a global BioNTech collaboration on the bispecific antibody pumitamig |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2025
| Total revenues | $48.19B (essentially flat YoY) |
| Gross profit | $34.26B |
| Operating income | $10.00B |
| Net earnings attributable to BMS | $7.05B |
| Diluted EPS | Not available |
| Operating cash flow | $14.16B |
| Total assets | $90.04B (Dec 31, 2025) |
| Research and development | Not available |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Bristol-Myers Squibb is the S&P 500’s large-cap biopharma transition story: at a 0.18% index weight and the #14 market cap in Health Care, it is the index’s main exposure to whether a legacy drug maker can rotate to growth products before its blockbusters expire.
Its results track the patent-cliff timetable for the whole sector — Growth Portfolio growth against Legacy decline is the single clearest quarterly read on that rotation.
SOURCES & METHODOLOGY
| Market data | Slickcharts S&P 500 by weight (rank, weight, price — Oct 29, 2026 crawl) |
| Financials | Bristol-Myers Squibb FY2025 Form 10-K (SEC EDGAR, filed Feb 11, 2026) |
| Sector classification | GICS (Pharmaceuticals) via the List of S&P 500 companies (Wikipedia) |
| Library data | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 代碼 | BMY(NYSE) |
| 公司 | Bristol-Myers Squibb Company |
| GICS 板塊/行業 | 醫療保健(XLV)/製藥 |
| 標普500排名(按權重) | #94 · 0.18%(2026 年 10 月 29 日) |
| 板塊內排名(按市值) | 醫療保健第 #14(2026 年 10 月 29 日) |
| 總部 | 美國新澤西州普林斯頓 |
| 成立 | 1887 年,Bristol-Myers Company(Squibb 創於 1858 年) |
| 行政總裁 | Christopher S. Boerner(主席兼行政總裁) |
| 員工 | ≈32,500(2025 年 12 月 31 日) |
| 市值 | $125.40B(2026 年 10 月 29 日)· 價格 $61.39 |
| SEC 申報 | EDGAR — CIK 0000014272 |
業務概覽
百時美施貴寶是一家全球生物製藥公司,研發、生產與銷售治療嚴重疾病的處方藥。公司以單一板塊申報,集中於腫瘤、血液、免疫、心血管與神經科學領域。FY2025 總收入為 $48.19B,與 FY2024 大致持平,其中 69% 來自美國。
兩大重磅藥仍是收入支柱:與輝瑞共同銷售的口服抗凝藥 Eliquis 為 $14.44B,免疫腫瘤抗體 Opdivo 為 $10.05B。圍繞它們,增長組合——Reblozyl($2.33B)、Breyanzi($1.36B)、Camzyos($1.07B)、Opdualag($1.19B)及獲批後首個完整年度的 Cobenfy($155M)——增長 17% 至 $26.41B;傳統組合則下跌 15% 至 $21.79B,Revlimid($2.95B)繼續受仿製藥侵蝕。
策略是一場與專利懸崖賽跑:在 Eliquis、Opdivo 與 Revlimid 失去專利保護前,以新藥與管線資產取代其收入,並以 $10.00B 的營業利潤為研發提供資金。與 BioNTech 就 pumitamig 的合作(2025 年首付款 $1.5B)是這場替代戰中最大的一注。
業務板塊 — FY2025 收入(按組合)
| 組合 | 收入 | 佔比 | 同比 |
|---|---|---|---|
| 增長組合 | $26.41B | 54.8% | +17% |
| 傳統組合 | $21.79B | 45.2% | −15% |
| 總收入 | $48.19B | 100% | 大致持平 |
歷史沿革
| 1858 | E. R. Squibb 創立 Squibb,生產純製藥品 |
| 1887 | William Bristol 與 John Myers 創立 Bristol-Myers Company |
| 1989 | Bristol-Myers 與 Squibb 合併為 Bristol-Myers Squibb Company |
| 2012 | Eliquis(apixaban)獲美國 FDA 批准用於房顫中風預防 |
| 2015 | Opdivo(nivolumab)獲美國 FDA 批准,奠定免疫腫瘤學地位 |
| 2019 | 完成收購 Celgene,取得 Revlimid 與血液學管線 |
| 2020 | 收購 MyoKardia,取得阻塞性肥厚型心肌病藥物 Camzyos |
| 2023 | 宣布收購 Karuna Therapeutics,取得精神分裂症藥物 Cobenfy |
| 2024 | Cobenfy 獲美國 FDA 批准用於精神分裂症;Karuna 交易完成 |
| 2025 | 與 BioNTech 達成全球合作,開發雙特異性抗體 pumitamig |
競爭地位
財務快照 — FY2025
| 總收入 | $48.19B(同比大致持平) |
| 毛利 | $34.26B |
| 營業利潤 | $10.00B |
| 歸屬 BMS 淨利潤 | $7.05B |
| 攤薄每股盈利 | Not available |
| 經營現金流 | $14.16B |
| 總資產 | $90.04B(2025 年 12 月 31 日) |
| 研發支出 | Not available |
主要風險
對標普500的重要性
百時美施貴寶是標普500中的大型生物製藥轉型故事:指數權重 0.18%、醫療保健板塊市值第 #14,是指數對傳統藥廠能否在重磅藥到期前完成增長產品輪換的主要敞口。
其業績追蹤整個行業的專利懸崖時間表——增長組合增長對傳統組合下滑,是這場輪換最清晰的季度讀數。
來源與方法
| 市場數據 | Slickcharts 標普500權重榜(排名、權重、價格——2026 年 10 月 29 日抓取) |
| 財務 | 百時美施貴寶 FY2025 Form 10-K(SEC EDGAR,2026 年 2 月 11 日申報) |
| 板塊分類 | GICS(製藥),據 S&P 500 公司清單(Wikipedia) |
| 圖庫數據 | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-10-30 04:29 · updated 2026-11-14 23:04 · rev 7